Is the price fair?
What AXSM's price assumes
Axsome Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 12.2× revenue.
12.2
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 159
Price / book · as of 2026-Q1
- EV / sales
- 11.9
EV / sales
Details›
- Price / book2026-Q1
- 159
- EV / EBIToperating margin −24%: the multiple describes the denominator
- not meaningful
- EV / sales2026-Q1
- 11.9
- Market capitalisation
- $12.9B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.